Gilead to present preclinical HIV study at CROI 2017

Gilead to present preclinical HIV study at CROI 2017

February 14, 2017 Off By Dino Mustafić

Gilead Sciences will present findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment, at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

The study identified novel HIV-1 capsid inhibitors with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro.

Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences said: “Capsid inhibition is a previously unexplored target for antiviral therapy and we are pleased to share these preclinical results showing the potential role of this class of therapy as a novel, long-acting injectable for HIV treatment and prevention in the future.

Gilead plans to evaluate a selected development candidate in Investigational New Drug (IND)-enabling toxicology studies and begin Phase 1 clinical trials in 2018.

The company noted that GS-CA1 is an investigational therapy and has not been determined to be safe or efficacious.